Metformin for clozapine associated obesity: A systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Siskind, Dan J ^a,b   Leung, Janni ^a,c   Russell, Anthony W ^a,d   Wysoczanski, Daniel ^a,b   Kisely, Steve ^a,b,e,f  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Metro South Addiction and Mental Health Service   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; NEUROLEPTIC AGENT;

ARTICLE; BLOOD PRESSURE; BODY MASS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; META ANALYSIS; METABOLIC SYNDROME X; OBESITY; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WEIGHT GAIN; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; DIET RESTRICTION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CLOZAPINE; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 84976303022     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156208     Document Type: Article

References (34)

1. Lawrence D, Hancock KJ, Kisely S (2013) The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 346: f2539. doi: 10.1136/bmj.f2539 PMID: 23694688
2. Ryan MCM, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289. PMID: 12562574
3. Rosenbaum S, Tiedemann A, Sherrington C, Curtis J, Ward PB (2014) Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry 75: 964-974. doi: 10.4088/JCP.13r08765 PMID: 24813261
4. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr Bull 39: 306-318. doi: 10.1093/schbul/sbr148 PMID: 22207632
5. National Institute for Health and Care Excellence (2014) Psychosis and schizophrenia in adults: treatment and management NICE clinical guideline 178. London: National Institute for Health and Care Excellence.
6. Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, et al (2011) An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 72: 1439-1444. doi: 10.4088/JCP.09m05785yel PMID: 21457676
7. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796. PMID: 3046553
8. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645. doi: 10.1161/CIRCULATIONAHA.109.192644 PMID: 19805654
9. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, et al (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66: 1116-1121. PMID: 16187768
10. Whitney Z, Procyshyn RM, Fredrikson DH, Barr AM (2015) Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol.
11. Zheng W, Li X-B, Tang Y-L, Xiang Y-Q, Wang C-Y, de Leon J (2015) Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 35: 499-509.
12. Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: an update. Ann Intern Med 137: 25-33. PMID: 12093242
13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403. PMID: 11832527
14. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE (2008) Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 121: 149-157.e2. doi: 10.1016/j.amjmed.2007.09.016 PMID: 18261504
15. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, et al (2001) Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24: 489-494. PMID: 11289473
16. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439. PMID: 17928588
17. Mayfield K, Siskind D, Winckel K, Russell A, Kisely S, et al (2015) Glucagon-like peptide-1 agonists combating clozapine- associated obesity and diabetes. Journal of Psychopharmacology in press.
18. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, et al (2012) The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 1: 2. doi: 10.1186/2046-4053-1-2 PMID: 22587842
19. (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
20. Hebrani P, Manteghi AA, Behdani F, Hessami E, Rezayat KA, et al (2015) Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. J Res Med Sci 20: 364-371. PMID: 26109992
21. Chen C-H, Huang M-C, Kao C-F, Lin S-K, Kuo P-H, et al (2013) Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 74: e424-e430. doi: 10.4088/JCP.12m08186 PMID: 23759461
22. Liu H (2012) Effects of metformin hydrochloride on body mass and blood sugar of convalescence schizophrenics on clozapine. J Clin Psychosom Dis 18: 97-98.
23. Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, et al (2009) Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113: 19-26. doi: 10.1016/j.schres.2009.05.007 PMID: 19515536
24. Wu R-R, Zhao J-P, Jin H, Shao P, Fang M-S, et al (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299: 185-193. doi: 10.1001/jama.2007.56-b PMID: 18182600
25. Wu R-R, Jin H, Gao K, Twamley EW, Ou J-J, et al (2012) Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 169: 813-821. doi: 10.1176/appi.ajp.2012.11091432 PMID: 22711171
26. Wu W, Wang SR, Liu H (2014) Metformin hydrochloride auxiliary clozapine impact on patients weight and blood sugar treatment refractory schizophrenia. Chinese People's Health 26: 68-69.
27. Wang X (2009) Metformin with Lifestyle Intervention in Treatment of Clozapine-induced Metabolic Disorders. Chinese General Practice 12: 840-842.
28. Björkhem-Bergman L, Asplund AB, Lindh JD (2011) Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol 25: 299-305. doi: 10.1177/0269881109353461 PMID: 20080925
29. Choi Y-J (2015) Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. ScientificWorldJournal 2015: 970730. doi: 10.1155/2015/970730 PMID: 25664341
30. Cohen JF, Korevaar DA, Wang J, Spijker R, Bossuyt PM (2015) Should we search Chinese biomedical databases when performing systematic reviews? Syst Rev 4: 23. doi: 10.1186/s13643-015-0017-3 PMID: 25874584
31. Xia J, Wright J, Adams CE (2008) Five large Chinese biomedical bibliographic databases: accessibility and coverage. Health Info Libr J 25: 55-61. doi: 10.1111/j.1471-1842.2007.00734.x PMID: 18251914
32. St Jeor ST, Brunner RL, Harrington ME, Scott BJ, Daugherty SA, et al (1997) A classification system to evaluate weight maintainers, gainers, and losers. J Am Diet Assoc 97: 481-488. PMID: 9145085
33. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333: 541-549. PMID: 7623902
34. Mayfield K, Siskind D, Winckel K, Hollingworth S, Kisely S, Russell AW (2015) Treatment of clozapineassociated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. British Journal of Psychiatry Open 1: 67-73.